European Journal of Epidemiology

, Volume 21, Issue 5, pp 389–396

Including pre-AIDS mortality in back-calculation model to estimate HIV prevalence in France, 2000

Infectious Diseases


Since the advent of highly active antiretroviral therapy (HAART) the lengthening of AIDS incubation time has led to a decrease of AIDS incidence and mortality, and to the increase of the proportion of pre-AIDS mortality. The objective was to develop an extension of the back-calculation model by including pre-AIDS mortality and to estimate HIV prevalence in France. Our previous back-calculation model was modified to take into account the probability of survival for HIV-infected individual using the relative risk to die at different period for an HIV-infected person versus the general population (ψ). AIDS cases reported to InVS (Institut de Veille Sanitaire) until March 2003 were back-calculated to estimate HIV incidence until December 2000. AIDS deaths occurring until December 2000 were used to obtain HIV prevalence in 2000. Plausible intervals were calculated taking into account uncertainties on AIDS incubation time. Taking into account pre-AIDS mortality increased the goodness-of-fit of the model to the data. The relative risk, ψ, was estimated as 3 for homo-bisexual men, haemophiliacs and transfused cases, 10 for intravenous drug users, and 4 for heterosexual cases, with no difference over period. HIV prevalence in 2000 was estimated as 88,200 (with a plausible interval of 52,300–168,000), versus 78,200 when mortality was not considered. Pre-AIDS mortality estimates show the amount of this mortality during the era of HAART but also evidenced its existence before HAART. Taking into account pre-AIDS mortality of HIV-infected person in the back-calculation model increased the estimated HIV prevalence.


Back-calculation method French Hospital Database on HIV HIV prevalence Pre-AIDS mortality 



acquired immunodeficiency syndrome


French Hospital Database on HIV


highly active antiretroviral therapy


human immunodeficiency virus


plausible interval


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS Int J Epidemiol 2005;34:121–130CrossRefPubMedGoogle Scholar
  2. 2.
    Louie J, Hsu LC, Osmond DH, Katz MH, Schwarcz SK. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Fransisco, 1994–1998 J Infect Dis 2002;186:1023–1027CrossRefPubMedGoogle Scholar
  3. 3.
    Mocroft A, Brettle R, Kirk O, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study AIDS 2002;16:1663–1671CrossRefPubMedGoogle Scholar
  4. 4.
    Deuffic S, Costagliola D. Is the AIDS incubation time changing? A backcalculation approach Stat Med 1999;18:1031–1047CrossRefPubMedGoogle Scholar
  5. 5.
    Deuffic-Burban S, Wong JB, Valleron A-J, Costagliola D, Delfraissy JF, Poynard T. Comparing the Public Health burden of chronic hepatitis C and HIV infection in France J Hepatol 2004;40:319–326CrossRefPubMedGoogle Scholar
  6. 6.
    Brookmeyer R, Gail M. The minimum size of the AIDS epidemic in the United States Lancet 1986;ii:1320–1322CrossRefGoogle Scholar
  7. 7.
    Brookmeyer R, Gail MH. A method for obtaining short term projections and lower bounds on the size of the AIDS epidemics J Am Stat Assoc 1988;83:301–308CrossRefGoogle Scholar
  8. 8.
    Tassie JM, Grabar S, Lancar R, Deloumeaux J, Bentata M, Costagliola D. Time to AIDS from 1992 to 1999 in HIV-1-infected subjects with known date of infection J Acquir Immune Defic Syndr 2002;30:81–87CrossRefPubMedGoogle Scholar
  9. 9.
    Brookmeyer R, Liao J. The analysis of delays in disease reporting: methods and results for the acquired immunodeficiency syndrome Am J Epidemiol 1990;132:355–365PubMedGoogle Scholar
  10. 10.
    Bernillon P, Lièvre L, Pillonel J, Laporte A, Costagliola D. Record-linkage between two anonymous databases for a capture-recapture estimation of underreporting of AIDS cases: France 1990–1993. The Clinical Epidemiology Group from Centres d’Information et de Soins de l’Immunodeficience Humaine Int J Epidemiol 2000;29:168–174CrossRefPubMedGoogle Scholar
  11. 11.
    Rapport Delfraissy. (2002) Prise en charge des personnes infectées par le VIH. Ministère de la Santé et de la Protection Sociale, Paris République FrançaiseGoogle Scholar
  12. 12.
    Fardet L, Mary-Krause M, Heard I, Partisani M, Costagliola D. Le sexe et le groupe de transmission de patients infectés par le VIH influencent-ils l’initiation d’un traitement anti-retroviral hautement actif et la réponse clinico-biologique sous traitement? In: 23ème réunion interdisciplinaire de chimiothérapie anti-infectieuse (RICAI); 4–5 Décembre, Paris, France; 2003; 55/10cGoogle Scholar
  13. 13.
    Lewden C, Raffi F, Chene G, Sobel A, Leport C. Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy: standardization to the general population J Acquir Immune Defic Syndr 2001;26:480–482PubMedGoogle Scholar
  14. 14.
    Lewden C. APROCO-COPILOTE Study Group, Aquitaine Cohort Study Group. Responders to antiretroviral treatment over 500 CD4/mm3 reach same mortality rates as general population: APROCO and Aquitaine cohorts, France. In: Proceedings of the 10th European AIDS Conference/EACS; Nov 17–20, 2005; Dublin, Ireland [PE18.4/8]Google Scholar
  15. 15.
    Becker NG, Marschner IC. A method for estimating the age-specific relative risk on HIV infection from AIDS incidence data Biometrika 1993;80:165–178CrossRefMathSciNetGoogle Scholar
  16. 16.
    Burnham K, Anderson D. (1998) Model Selection and Inference: A Practical Information – Theoretical Approach. Springel-Verlag, New-YorkGoogle Scholar
  17. 17.
    Efron B, Gong G. A leisurely look at the bootstrap, the jackknife, and cross-validation Amer Statist 1983;37:36–48CrossRefGoogle Scholar
  18. 18.
    Schwartländer B, Stanecki KA, Brown T, et al. Country-specific estimates and models of HIV and AIDS: methods and limitations AIDS 1999;13:2445–2458CrossRefPubMedGoogle Scholar
  19. 19.
    The UNAIDS Reference Group on Estimates MaP. Improved methods and assumptions for estimation of the HIV/AIDS epidemic and its impact: Recommandations of the UNAIDS Reference Group on Estimates, Modelling and Projections AIDS 2002;16:W1–W14CrossRefGoogle Scholar
  20. 20.
    Walker N, Stanecki KA, Brown T, et al. Methods and procedures for estimating HIV/AIDS and its impact: the UNAIDS/WHO estimates for the end of 2001 AIDS 2003;17:2215–2225CrossRefPubMedGoogle Scholar
  21. 21.
    Detels R, Muñoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration JAMA 1998;280:1497–1503CrossRefPubMedGoogle Scholar
  22. 22.
    Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Walker AS. Determinants of survival following HIV-1 seroconversion after the introduction of HAART Lancet 2003;362:1267–1274CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  1. 1.CRESGE-LEMCNRS UMR 8179LilleFrance
  2. 2.INSERM U720ParisFrance
  3. 3.Cresge-LaboresCNRS URA 362Lille CedexFrance

Personalised recommendations